Masyar Gardizi

Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

Christine M. Lovly, Nerina T. McDonald, Heidi Chen et al. · Nature Medicine · 2014 · 267 citations · Full text

Medicine, Molecular Medicine, Oncology +12

<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung

Hans‐Ulrich Schildhaus, Anne M. Schultheis, Josef Rüschoff et al. · Clinical Cancer Research · 2014 · 189 citations

Medicine, Genetics, Oncology +17

<i>PIK3CA</i> mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies

Matthias Scheffler, Marc Bos, Masyar Gardizi et al. · Oncotarget · 2014 · 145 citations · Full text

Medicine, Genetics, Oncology +17

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Sebastian Michels, Bartomeu Massutí, Hans‐Ulrich Schildhaus et al. · Journal of Thoracic Oncology · 2019 · 131 citations · Full text

Medicine, Oncology, Pharmacology +14

Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified <i>FGFR1</i> in Lung Cancer

Florian Malchers, Felix Dietlein, Jakob Schöttle et al. · Cancer Discovery · 2013 · 94 citations

Medicine, Molecular Biology, Oncology +17